Posted by Michael Wonder on 13 Jul 2019
Esperoct is now approved in Canada for the treatment of haemophilia A in both children and adults
12 July 2019 - New treatment can help Canadians living with haemophilia A better manage their bleeding episodes
Novo Nordisk announced today that Health Canada has approved Esperoct (anti-haemophilic Factor VIII (Recombinant, B-Domain Truncated), PEGylated) for use in adults and children with haemophilia A (congenital Factor VIII deficiency) for:
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Peri-operative management of bleeding
Health Canada's approval is based on the findings from three multinational, open-label, non-controlled trials in male subjects with severe haemophilia A, which is defined as having less than 1 per cent of the normal level of factor VIII in the blood.
